RxDoctor Payments DataLook up a doctor →

Steve Dorman, MD

Allergy & Immunology · Jacksonville, FLNPI 1043519333

Payments from drug & device makers

$296,541in general payments, 2019–2025

Across 445 payments — averaging $666.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$111K
  • Novartis$98K
  • Takeda Pharmaceuticals U.S.A., Inc.$38K
  • Ionis Pharmaceuticals, Inc.$24K
  • Biocryst US Sales Co., LLC$9K
  • Genentech, Inc.$6K
  • plus $10K from 19 others

What the payments were for

  • Consulting fees$54,47426%
  • Speaking & faculty fees$131,09063%
  • Travel & lodging$12,3156%
  • Food & beverage$9,5245%
  • Education$1190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$296,541 in reported general payments places this provider in the 90th percentile of 204 allergy & immunology providers in Florida.

See all allergy & immunology providers in Florida

Medicare billing

Part B allowed, 2024
$529,096
Medicare patients
326
Services billed
22,968

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XolairOmalizumab58$193,116
CuvitruImmun Glob G(Igg)/Gly/Iga Ov5028$83,548
TezspireTezepelumab-Ekko15$78,353
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5017$64,984
Trelegy ElliptaFluticasone/Umeclidin/Vilanter74$54,798
Dupixent PenDupilumab11$40,344
Breo ElliptaFluticasone/Vilanterol57$22,640
SymbicortBudesonide/Formoterol Fumarate19$5,649
Ipratropium Bromide97$3,770
Wixela InhubFluticasone Propion/Salmeterol22$3,603
Epinephrine25$3,354
Fluticasone Propionate194$2,952
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$2,464
Azelastine Hcl119$2,462
Albuterol Sulfate HfaAlbuterol Sulfate120$2,239

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Genentech, Inc.Xolair$5,839$193,11658 claims
Takeda Pharmaceuticals U.S.A., Inc.Cuvitru, Gammagard Liquid$38,419$148,53245 claims
AstraZenecaTezspire, Symbicort$110,563$84,00234 claims
GSKTrelegy Ellipta, Breo Ellipta$192$77,438131 claims
Hikma Pharmaceuticals USAEpinephrine$35$3,35425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 204 allergy & immunology providers in Florida.

Other allergy & immunology in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →